Research programme: anti-infectives - Xellia Pharmaceuticals
Latest Information Update: 28 Mar 2025
At a glance
- Originator Xellia Pharmaceuticals
- Developer SINTEF Materials and Chemistry; Statens Serum Institut; Xellia Pharmaceuticals
- Class Antibacterials; Polymixins
- Mechanism of Action Cell membrane modulators; Cell wall inhibitors; Lipopolysaccharide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cystic fibrosis-associated respiratory tract infections; Gram-negative infections; Gram-positive infections
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for research development in Cystic-fibrosis-associated-respiratory-tract-infections in Norway (Parenteral, Inhalant)
- 28 Mar 2025 No recent reports of development identified for research development in Gram-negative-infections in Norway (Parenteral)
- 28 Mar 2025 No recent reports of development identified for research development in Gram-positive-infections in Norway (Parenteral)